Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 6/20 | 0.38 |
| ▸ | RAB9A | P51151 | 5/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | TACR3 | P29371 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13666327 | 0.84 | SMN1; SMN2 (0.41) | SMN1; SMN2POLBNPC1RAB9AHTT | |
| SCHEMBL14140248 | 0.78 | SMN1; SMN2 (0.46) | SMN1; SMN2NPC1RAB9AHTTTDP1 | |
| SCHEMBL12188234 | 0.75 | L3MBTL1 (0.46) | SMN1; SMN2POLBNPC1RAB9AHTT | |
| SCHEMBL10100319 | 0.74 | NPC1 (0.38) | NPSR1SMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL10094548 | 0.71 | MAOA (0.56) | SMN1; SMN2POLBNPC1RAB9AALDH1A1 | |
| SCHEMBL23791454 | 0.71 | HSD11B1 (0.35) | KMT2AMEN1 | |
| SCHEMBL20910824 | 0.71 | ZAP70 (0.45) | NPSR1SMN1; SMN2POLBNPC1RAB9A | |
| SCHEMBL16018752 | 0.70 | NPSR1 (0.46) | NPSR1SMN1; SMN2POLBNPC1RAB9A | |
| SCHEMBL10248988 | 0.70 | SMN1; SMN2 (0.54) | NPSR1SMN1; SMN2POLBNPC1RAB9A | |
| SCHEMBL13218155 | 0.69 | TRPA1 (0.38) | NPSR1SMN1; SMN2NPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9290454-B2 | Substituted isoquinolines as CRTH2 receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20150353498-A1 | SUBSTITUTED ISOQUINOLINES AS CRTH2 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2015-12-10 | — | — | US | disclosed |
| US-8143268-B2 | Bicyclic pyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2012-03-27 | — | — | US | disclosed |
| US-8143268-B2 | Bicyclic pyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2012-03-27 | — | — | US | disclosed |
| US-20100168063-A1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2010-07-01 | — | — | US | disclosed |
| US-20100168063-A1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168063-A1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | TPMT, TYMP, DPYD | NPSR1 1957/4885SMN1; SMN2 1064/4885POLB 679/4885 |
| US-20150353498-A1 | SUBSTITUTED ISOQUINOLINES AS CRTH2 RECEPTOR MODULATORS | NR1H2, NR1H3, GPR52 | NPSR1 186/4885SMN1; SMN2 3451/4885POLB 4311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.